GlassScriptPhysician profile
Staci L Hopper
NPI 1659345247
$6,203.28
in general payments reported to CMS, 2019-2025
31 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $865 · 2022: $771 · 2023: $1,561 · 2024: $1,453 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,401 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,400.98 |
| Education | $166.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,029.08 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $896.29 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.68 | 2021-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $456.37 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $409.34 | 2023-2025 | Winrevair, Dificid, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $367.68 | 2021-2025 | Acthar |
| Grifols USA, LLC | $353.11 | 2021-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $306.96 | 2022-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $262.18 | 2022-2025 | Glassia |
| Baxter Healthcare | $205.08 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $147.89 | 2021-2024 | Yupelri |
| Philips North America LLC | $139.91 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Abbvie INC. | $128.92 | 2021-2025 | |
| Gilead Sciences, INC. | $121.04 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $104.59 | 2021-2025 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $97.24 | 2023-2025 | |
| Insmed, INC. | $93.22 | 2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $78.09 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Ani Pharmaceuticals, INC. | $74.65 | 2022-2025 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $60.56 | 2021 | |
| Electromed, INC. | $54.76 | 2025 | Smartvest |
| Viatris Specialty LLC | $54.21 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $44.42 | 2023 | Giapreza |
| Pfizer INC. | $33.13 | 2024 | |
| Amgen INC. | $33.05 | 2023-2025 | Tezspire |
| Chiesi USA, INC. | $28.53 | 2023 | Bronchitol |
| Inari Medical, INC. | $27.14 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $21.05 | 2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $16.54 | 2021 | |
| Vapotherm INC | $16.31 | 2021 | |
| Genentech USA, INC. | $15.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.